RS&RS Scientific Ltd

Contact information
Salimi Reza
Share on:
Mini-bio

RS&RS Scientific Ltd. is a UK-based biotechnology company developing inhalable precision gene therapies to treat aggressive and drug-resistant cancers, starting with small-cell lung cancer. Founded by scientists with over 30 years of combined expertise in molecular medicine, gene therapy, and cancer biology, RS&RS Scientific aims to redefine cancer treatment through targeted, non-invasive delivery systems that act directly in the lungs, minimize systemic toxicity, and improve patient quality of life.

Backed by Innovate UK, SFC Capital, and Discovery Park Ventures, the company is advancing from in vitro proof-of-concept to in vivo validation, paving the way for future clinical translation and strategic partnerships with leading pharmaceutical firms.

Core goals

Revolutionize Lung Cancer Treatment: Develop and commercialize the first inhalable precision gene therapy for small cell lung cancer, directly targeting tumors in the lungs with minimal systemic toxicity.

Overcome Drug Resistance: Inhibit genes responsible for tumor recurrence and treatment resistance, transforming the tumor microenvironment from “cold” to “inflamed” to boost immune response.

Enable Home-Based Care: Create a non-invasive, patient-friendly inhalation therapy that can be administered outside hospital settings, improving quality of life and treatment accessibility.

Strengthen Intellectual Property: Secure robust IP protection for our nanoparticle delivery platform and tumor-specific promoter technology to support future licensing and clinical partnerships.

Achieve Preclinical and Commercial Readiness: Complete in vivo validation by 2026, finalize regulatory documentation, and position RS&RS Scientific for strategic collaboration or acquisition with major pharmaceutical companies.

ESG Subnetwork
Join this Subnetwork
Innovation Subnetwork
Join this Subnetwork
Investor Subnetwork
Members (2)
Join this Subnetwork
Business roadmap
Milestones (11)
Created on: Oct, 22 2025